Allogene Therapeutics Inc’s recently made public that its Director MESSEMER DEBORAH M. unloaded Company’s shares for reported $32351.0 on Feb 18 ’25. In the deal valued at $2.43 per share,13,313 shares were sold. As a result of this transaction, MESSEMER DEBORAH M. now holds 144,316 shares worth roughly $0.29 million.
Then, MESSEMER DEBORAH M. bought 13,313 shares, generating $32,329 in total proceeds.
Before that, Douglas Earl Martin sold 6,404 shares. Allogene Therapeutics Inc shares valued at $10,951 were divested by the SVP, General Counsel at a price of $1.71 per share. As a result of the transaction, Douglas Earl Martin now holds 587,848 shares, worth roughly $1.17 million.
A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in late May with a ‘”an Overweight”‘ rating. JMP Securities also remained covering ALLO and has decreased its forecast on January 05, 2024 with a “Mkt perform” recommendation from previously “Mkt outperform” rating. Guggenheim revised its rating on January 05, 2024. It rated ALLO as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ALLO
On Tuesday, Allogene Therapeutics Inc [NASDAQ:ALLO] saw its stock fall -7.24% to $1.99. Over the last five days, the stock has lost -30.11%. Allogene Therapeutics Inc shares have fallen nearly -6.81% since the year began. Nevertheless, the stocks have fallen -54.47% over the past one year. While a 52-week high of $5.78 was reached on 02/19/25, a 52-week low of $1.32 was recorded on 02/12/25. SMA at 50 days reached $1.96, while 200 days put it at $2.45.
Levels Of Support And Resistance For ALLO Stock
The 24-hour chart illustrates a support level at 1.89, which if violated will result in even more drops to 1.79. On the upside, there is a resistance level at 2.11. A further resistance level may holdings at 2.24. The Relative Strength Index (RSI) on the 14-day chart is 50.51, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.21, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.97%. Stochastics %K at 31.64% indicates the stock is a holding.
The most recent change occurred on December 08, 2023 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
